Cover

TIA as Acute Cerebrovascular Syndrome

Editor(s): Uchiyama S. (Tokyo) 
Amarenco P. (Paris) 
Minematsu K. (Osaka) 
Wong K.S.L. (Hong Kong) 
Table of Contents
Vol. 33, 2014
Section title:  
Uchiyama S, Amarenco P, Minematsu K, Wong KSL (eds): TIA as Acute Cerebrovascular Syndrome. Front Neurol Neurosci. Basel, Karger, 2014, vol 33, pp 135-146
(DOI:10.1159/000351914)

Stroke Subtypes and Interventional Studies for Transient Ischemic Attack

Lavallée P. · Amarenco P.
INSERM U-698, Department of Neurology and Stroke Center, AP-HP, Bichat-Claude Bernard Hospital, University Paris Diderot, Sorbonne Paris Cité, Paris, France

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 33.00
Account: USD 23.00

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price


Select


Article / Publication Details

First-Page Preview
Abstract of  

Published online: 10/11/2013
Cover Date: 2014

Number of Print Pages: 12
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-318-02458-6 (Print)
eISBN: 978-3-318-02459-3 (Online)

Abstract

Transient ischemic attack (TIA) is the most important risk factor for ischemic stroke. The risk is the highest in the first hours after symptom onset, and treatment must be initiated in emergency. In the acute phase, antithrombotic agent is probably the most important treatment, but it is not excluded that lipid-lowering agents and/or antihypertensive drugs are also important. For current guidelines, monotherapy of antiplatelet agent remains the gold standard in emergency. However, most recent data and meta-analysis support a combination therapy of clopidogrel and aspirin. Data on treatment in the very acute phase of TIA in the different etiologic stroke subtypes are also lacking especially for cardioembolic stroke and the potential benefit of anticoagulant. Long-term prevention mainly derived from large trials, in which TIA and minor stroke patients have constituted the largest part. Patients with non-cardioembolic stroke must be treated with antiplatelet agent in monotherapy, and dual antiplatelet therapy such as clopidogrel plus aspirin should be avoided, particularly in lacunar strokes, whereas anticoagulants are the treatment of choice for patients with cardioembolic stroke. Major advances concerning stroke prevention in patients with atrial fibrillation have emerged with new oral anticoagulant agents that are as effective as vitamin K antagonists and safer, especially with regard to the risk of intracranial hemorrhage. At variance with moderate and severe cerebral infarction, oral anticoagulants can be initiated without delay in TIA patients. Left atrial appendage closure seems to be a promising treatment in patients ineligible for anticoagulation. Aggressive management of vascular risk factors, including blood pressure as low as 130/80 mm Hg, intensive statin treatment, smoking cessation and diabetes control, also plays a major role in the prevention of vascular event.


  

Author Contacts

Prof. Pierre Amarenco
Department of Neurology and Stroke Centre, AP-HP, Bichat-Claude Bernard Hospital
University Paris Diderot, Sorbonne Paris Cité, INSERM U698
46, rue Henri Huchard, FR-75018 Paris (France)
E-Mail pierre.amarenco@bch.aphp.fr

  

Article Information

Published online: October 11, 2013
Number of Print Pages : 12
Number of Figures : 0, Number of Tables : 0, Number of References : 49

  

Publication Details

Book Serie: Frontiers of Neurology and Neuroscience, Vol. 33, Year 2014 ISSN: 1660-4431 (Print), eISSN: 1662-2804 (Online)

For additional information:
http://www.karger.com?issn=1660-4431

Book Title: TIA as Acute Cerebrovascular Syndrome

Editor(s): Uchiyama S, Amarenco P, Minematsu K, Wong KSL (eds)

For additional information:
http://www.karger.com?issn=1660-4431&volume=33


Article / Publication Details

First-Page Preview
Abstract of  

Published online: 10/11/2013
Cover Date: 2014

Number of Print Pages: 12
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-318-02458-6 (Print)
eISBN: 978-3-318-02459-3 (Online)


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.